DSP-5336 targets the menin and mixed-lineage leukemia protein interaction, crucial in various biological processes, including cell growth and genomic stability. The FDA has granted Fast Track Designation to Sumitomo Pharma America’s DSP-5336, an investigational small molecule inhibitor for the treatment of relapsed or refractory acute myeloid leukemia (AML) with KMT2A rearrangement (MLLr) or nucleophosmin mutation (NPM1m). According to the company, DSP-5336 targets the menin and mixed-lineage leukemia (MLL) protein interaction, which is considered vital in a variety of biological processes, including cell growth and genomic stability.1.

FDA Grants Fast Track Designation to Sumitomo Pharma’s Novel Treatment for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Cancer Health

Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments. The five-drug combination targets multiple molecular pathways that diffuse large B-cell lymphoma (DLBCL) tumors use to survive.

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma

A novel personalized cellular immunotherapy approach may be effective at treating certain patients with metastatic solid tumors, according to early findings from a recent study published by Parkhurst et al in Nature Medicine. Background. Chimeric antigen receptor (CAR) T-cell therapy has already shown efficacy in some hematologic malignancies, and tumor-infiltrating...

Novel Immunotherapy Approach in Metastatic Solid Tumors

A few months back, good news hit the multiple myeloma community: the U.S. Food & Drug Administration voted to accept a new endpoint — MRD, or measurable residual disease — for accelerated approval of treatments for this cancer. What does this mean for myeloma patients?. Everything, per Fred...

When It Comes to Cancer Trials, What’s the (End)point?

Factors such as age, sex, and family history can impact a person’s risk of getting pancreatic cancer. It is more likely to occur later in life. Certain conditions can also increase the likelihood of pancreatic cancer. Pancreatic cancer develops in the tissues of the pancreas. This organ secretes digestive...

Who is most likely to get pancreatic cancer?

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

NewSantaAna

The FBI has seen a rise in scams targeting timeshare owners. In this kind of scam, criminals con these part-time property owners into shelling out hefty sums of cash, all under false pretenses related to their timeshare properties.

FBI warns that Mexican cartels are targeting Americans with timeshare scams

Eli Lilly said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early as the end of the year. The company released additional data from two late-stage trials showing that...

Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year

Emerging data from Phase I first-in-human, dose-escalation study showed promising survival and progression-free survival rates. The FDA has granted Fast Track Designation to Obsidian Therapeutics’ OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), for the treatment of patients with metastatic or locally advanced melanoma that is refractory to or has relapsed after PD-1/PD-L1–based immune checkpoint inhibitors (ICI).1.

FDA Grants Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma

Since his diagnosis with incurable Stage IV brain cancer in 2023, Australian doctor Richard Scolyer revealed that he has been cancer-free for a year after undergoing a world-first treatment based on his own research on immunotherapy to treat melanoma, a type of skin cancer, according to BBC. Last year, following...

Doctor Is Cancer-Free Following World-First Treatment He Developed

NF2-related schwannomatosis is a relentlessly progressive tumor predisposition syndrome with no FDA-approved treatments. Results from the Phase II INTUITT-NF2 trial (NCT04374305) show brigatinib produced radiographic responses across multiple tumor types with a clinical benefit in heavily pretreated patients with NF2-related schwannomatosis (NF2-SWN). The relentlessly progressive tumor predisposition syndrome is manifested via multiple vestibular schwannomas, nonvestibular schwannomas, meningiomas, and ependymomas.1,2.

Brigatinib Shows Clinical Benefit Across Multiple Tumor Types in Patients with NF2-Related Schwannomatosis with Progressive Tumors

T3D reveals a significant relationship between brain dysfunction and glucose levels, a critical factor in AD. Insufficient glucose levels can lead to an aggressive decline in insight, judgment, memory, and reasoning. Limited research reveals a link between Alzheimer’s disease and type 2 diabetes. Additional research is needed to understand...

What Is Type 3 Diabetes?

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare condition causing the growth of benign skin tumors and increasing the risk of a specific kidney cancer. HLRCC is an inherited condition. People with HLRCC develop multiple harmless skin tumors called leiomyomas, which can also develop in the uterus as fibroids.

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)

[On June 27], the Centers for Disease Control and Prevention (CDC) recommended the updated 2024-2025 COVID-19 vaccines and the updated 2024-2025 flu vaccines to protect against severe COVID-19 and flu this fall and winter. It is safe to receive COVID-19 and flu vaccines at the same visit. Data continue to...

CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus Season

Chicago, IL

Writers represent independent, third-party users who have joined our contributor program and self-verified their accounts. Writers are expected, like all users, to adhere to our Community Standards.

writer

Foodie in Chicago

Shortly before 3 AM, people in the Chicago area may have felt their houses shake as a 3.4-magnitude earthquake occurred about 60 miles west of the city. (CHICAGO) The United States Geological Survey (USGS) reported a 3.4-magnitude earthquake around Somonauk, IL. Somonauk is in DeKalb and LaSalle Counties, 64 miles west of Chicago.

Did You Feel the Earthquake?

The signs that thyroid cancer has spread can vary depending on where in the body it has traveled to. Thyroid cancers often spread to the nearby lymph nodes and the lungs, bone, brain, and liver. For all types of thyroid cancer, early detection and personalized treatment plans are crucial for...

What are some signs that thyroid cancer has spread?

New data show that nearly one third (31%) of adults worldwide, approximately 1.8 billion people, did not meet the recommended levels of physical activity in 2022. The findings point to a worrying trend of physical inactivity among adults, which has increased by about 5 percentage points between 2010 and 2022.

Nearly 1.8 Billion Adults at Risk of Disease From Not Enough Physical Activity

Using health data from almost 213,000 Americans who experienced reinfections, researchers have found that severe infections from the virus that causes COVID-19 tend to foreshadow similar severity of infection the next time a person contracts the disease. Additionally, scientists discovered that long COVID was more likely to occur after a first infection compared to a reinfection.

Study Suggests Reinfections With COVID-19 Virus Likely Have Similar Severity

Patients with pre-treated relapsed or refractory follicular lymphoma have shown benefits with mosunetuzumab. High-risk participants with heavily pre-treated relapsed or refractory follicular lymphoma (FL) benefited from mosunetuzumab in terms of clinical remission and survival outcomes. The benefit of mosunetuzumab was consistent in participants who had disease progression within 2 years (POD24), a factor associated with poor outcomes.

Mosunetuzumab Benefits Outcomes Across Follicular Lymphoma Subgroups

A new study led by American Cancer Society (ACS) researchers shows less than one-in-five eligible individuals in the United States were up-to-date (UTD) with recommended lung cancer screening (LCS). The screening uptake was much lower in persons without health insurance or usual source of care and in Southern states with the highest lung cancer burden. The findings are published June 10 in JAMA (Journal of the American Medical Association) Internal Medicine.

Most Eligible U.S. Adults Not Getting Screened for Lung Cancer

New Jersey State

Morristown Minute

NEW JERSEY - Attorney General Matthew J. Platkin and the Division of Consumer Affairs announced today that Walmart has agreed to pay $1.64 million to settle allegations of unlawful unit pricing practices across its 64 New Jersey retail stores. The settlement, which includes a $1.61 million civil penalty, marks the largest ever obtained by the Division’s Office of Weights and Measures (OWM).

Walmart Pays $1.64M Settlement for Unlawful Pricing in NJ

NewsBreak

FDA Approves Two First-Line Immunotherapies for Endometrial Cancer

The Food and Drug Administration (FDA) has approved two immune checkpoint inhibitor regimens as initial treatment for people with advanced or recurrent endometrial cancer. Merck’s Keytruda...

FDA Approves Two First-Line Immunotherapies for Endometrial Cancer

Comments / 0